4,6-di(naphthalen-2-yl)-8,15-dihydro-1H-quinolino[8′,1′:2,3,4][1,4]oxazocino-[6,7-b]-quinoxalin-1-one | 1190620-47-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮
• 英文名称: 4,6-di(naphthalen-2-yl)-8,15-dihydro-1H-quinolino[8′,1′:2,3,4][1,4]oxazocino-[6,7-b]-quinoxalin-1-one
• 英文别名: 4,6-Di(naphthalen-2-yl)-8,15-dihydro-1h-quinolino[8',1':2,3,4][1,4]oxazocino[6,7-b]quinoxalin-1-one；16,18-dinaphthalen-2-yl-14-oxa-1,4,11-triazapentacyclo[13.7.1.03,12.05,10.019,23]tricosa-3,5,7,9,11,15,17,19(23),20-nonaen-22-one
• CAS: 1190620-47-3
• 化学式: C₃₉H₂₅N₃O₂
• 分子量: 567.646
• InChiKey: CJFOSWBXASCFIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  44
• 可旋转键数：
  2
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  55.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5,7-dibromoquinolonoquinoxalino-oxazocine 、 2-萘硼酸 在 三苯基膦钯 作用下， 以 水 为溶剂， 反应 12.0h， 以95%的产率得到4,6-di(naphthalen-2-yl)-8,15-dihydro-1H-quinolino[8′,1′:2,3,4][1,4]oxazocino-[6,7-b]-quinoxalin-1-one
  参考文献：
  名称：

  Synthesis of biaryl pentacyclic quinolonoquinoxalino-oxazocines in aqueous medium using Amberlite IRA 402(OH)

  摘要：

  Amberlite IRA 402(OH) effectively mediates biarylation via Suzuki-Miyaura cross-coupling reaction on complex systems such as dihalo quinolonoquinoxalino-oxazocines. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2009.07.072

文献信息

• Combined palladium/eosin Y-catalysed direct synthesis of anticancer biarylquinolinooxazocino-quinoxaline-1-ones under visible light in one-pot sequence: a revisited proof of concept
  作者：Nilmadhab Roy、Priyankar Paira

  DOI：10.1007/s00706-020-02641-2

  日期：2020.7

  A novel, efficient, and green catalytic system under visible light irradiation has been introduced for the synthesis of anticancer biarylquinolooxazocino-quinoxaline-1-ones in one-pot sequence. The developed synthetic approach will be successfully utilized for the synthesis of various bioactive biarylquinolone in near future. Also, the cytotoxicity profile of these scaffolds has unveiled their superb cytoselectivity in HeLa and MCF-7 cell line compared to cisplatin. Graphic abstract